Navigation Links
Profil Institute Continues to Publish New Findings in Metabolic Research
Date:3/21/2012

SAN DIEGO, March 21, 2012 /PRNewswire/ -- Profil® Institute for Clinical Research, Inc., a company focused on early phase clinical trials for diabetes and obesity, announced today its continued focus on contributing to scientific research in the public domain. The company published research on new therapies in diabetes in nine scientific journals last year and one of its key scientists Prof. Andrew Krentz has authored two textbooks on drug therapy for type 2 diabetes, due to publish this summer.

"We are in a notable position of having been involved in clinical research in almost every promising diabetes-related therapy and in all key anti-diabetic drug categories, benefiting diabetes research as a whole," said Dr. Marcus Hompesch, Profil Institute CEO. "Profil Institute's scientists hail from the world's most renowned institutes and universities focused on diabetes and other metabolic disorders, and we believe strongly in continuing to contribute to the advancement of scientific research in the public domain." 

A list of the company's most recent publications is available on Profil Institute's website www.profilinstitute.com under Scientific Expertise with abstracts or full articles available at the US National Library of Medicine's website www.pubmed.gov

Scientific journals include Journal of Diabetes Science and Technology; Diabetes Technology and Therapeutics; Diabetes, Obesity and Metabolism; Diabetes Care; and Treatment Strategies Diabetes.

The two textbooks Drug Therapy for Type 2 Diabetes (London: Adis, 2012, in press) and Pharmacotherapy for Type 2 Diabetes (London: Royal Society of Medicine Press, 2012, in press) are authored by Prof. Andrew Krentz, Profil Institute's Senior Director of Scientific Services.

The textbooks present detailed coverage of established glucose-lowering drugs and recently-introduced therapy options for type 2 diabetes.  Most notably for physicians, the textbooks discuss how to integrate newer drugs in the context of established drug therapy, guidelines and treatment algorithms. Both textbooks are expected to publish later this summer.

About Profil® Institute for Clinical Research, Inc.

Profil Institute's advances in early phase drug research and its specific focus on diabetes, obesity and cardiometabolic diseases as it relates to the diabetic patient population have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug trials. 

To date, Profil Institute has been involved with almost every clinically promising drug category and device development in diabetes and in more than 175 clinical studies since the company's inception in 2004. Contributing to Profil Institute's success is that the company is recognized as the leader in automated glucose clamps, considered the "Gold Standard" for the evaluation of anti-diabetic drugs and devices.  The company's key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Dusseldorf, Columbia University, University of Michigan and Harvard University. For more information visit www.profilinstitute.com.

 

 


'/>"/>
SOURCE Profil Institute for Clinical Research, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Profiler at the cellular level
2. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
3. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
4. Precision Therapeutics Announces New Tumor Profiling Product to Augment Utility of ChemoFx® and Further Personalize Cancer Treatment
5. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
6. Reportlinker Adds Merck KGaA: PharmaVitae Profile
7. Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets
8. Reportlinker Adds Shire plc: PharmaVitae Profile
9. Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome
10. DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
11. Profil Institutes Dr. Marcus Hompesch Named Finalist in Ernst & Young Entrepreneur Of The Year(R) 2010 Award for Second Year in a Row
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated network ... two long-standing principal investigators (PI) to the roles of Chief Medical Officer, Clinical ... Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will assume ...
(Date:2/10/2016)... ... 2016 , ... SonaCare Medical, LLC reports the introduction of ... monitoring. The inaugural launch of this new technology occurred over the course of ... to a HIFU technical expert at SonaCare Medical headquarters. , Sonalink allows ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... a new agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate ... and Singapore in the latest adipose and bone marrow therapies. , Through ...
Breaking Biology Technology:
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
(Date:1/18/2016)... 2016  Extenua Inc., a pioneering developer of ... and access of ubiquitous on-premise and cloud storage, today ... Cyber.  ... C4ISR and Cyber initiatives in support of National ... technology solutions," said Steve Visconti , Extenua ...
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
Breaking Biology News(10 mins):